Trial Profile
Entyvio (Vedolizumab) Long-term Safety Study: An International Observational Prospective Cohort Study Comparing Vedolizumab to Other Biologic Agents in Patients With Ulcerative Colitis or Crohn's Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jun 2023
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions
- Acronyms Entyvio PASS
- Sponsors Takeda
- 09 May 2023 Results (n=465) of a post-hoc analysis of fatigue registry data of Belgian patients being followed in a prospective real-world safety study presented at the Digestive Disease Week 2023
- 13 Aug 2021 Status changed from active, no longer recruiting to completed.
- 12 Apr 2021 Planned End Date changed from 22 Jul 2021 to 30 Jul 2021.